THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Repatha is approved in more than 70 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union. Applications in other countries are pending. Important ...

Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled ...

The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

Repatha is approved in more than 70 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union. Applications in other countries are pending. Important ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

The government’s approval of a new drug to lower cholesterol could mean billions of dollars for Thousand Oaks biotech giant Amgen — and spark a new round of debate over the thousands of dollars it ...

The new sBLA is supported by data from a study which assessed MACE outcomes in 27,564 patients The Food and Drug Administration (FDA) has granted Priority Review for Amgen’s supplemental Biologics ...